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ABSTRACT
Background Despite evidence for the beneﬁts of
vitamin A supplementation (VAS) among children 6 to
59 months of age, the feasibility of introduction and
potential beneﬁt of VAS in the neonatal period in public
health programmes is uncertain.
Objective The primary objective was to evaluate the
feasibility and effectiveness of early neonatal VAS (single
dose of 50 000 international units within 48–72 hours
after birth) delivered through the public sector Lady
Health Worker (LHW) programme in rural Pakistan and
to document its association with a reduction in mortality
at 6 months of age.
Methods A community-based, cluster randomised,
placebo-controlled trial was undertaken in two districts
of rural Pakistan. LHWs dispensed vitamin A/placebo in
identical capsules to newborn infants within 48–
72 hours of birth. Follow-up visits were undertaken at
1 week of age and every 4 weeks thereafter until
6 months of age.
Results Of a total of 15 433 consecutive pregnancies
among eligible women of reproductive age, 13 225
pregnancies were registered, 12 218 live births identiﬁed
and 11 028 newborn infants reached by LHWs. Of
these, 5380 (49%) received neonatal VAS and 5648
(51%) placebo. The LHWs successfully delivered the
capsules to 79% of newborns within 72 hours of birth
with no signiﬁcant adverse effects. Although the
proportion of days observed with symptoms of fever,
diarrhoea or rapid breathing were lower with neonatal
VAS, these differences were not statistically signiﬁcant.
Mortality rates in the two groups were comparable at
6 months of age.
Conclusions While our study demonstrated that
neonatal VAS was safe and could be feasibly delivered
by LHWs in Pakistan as part of their early postnatal
visits, the overall lack of beneﬁt on neonatal and 6-
month morbidity and mortality in our population
suggests the need for further evaluation of this
intervention in populations at risk.
Trial registration number ClinicalTrials.gov
NCT00674089.
INTRODUCTION
Globally, 6.3 million children die each year before
reaching their ﬁfth birthday and almost 44% of
these deaths occur during the ﬁrst 28 days of life.1
Annually, 2.9 million neonatal deaths are reported
globally that are largely preventable.2 3 Maternal
and childhood undernutrition contributes to almost
45% of child deaths and the association of vitamin
A deﬁciency with excess risk of child morbidity and
mortality after 6 months of age is well recognised.4
Vitamin A supplementation (VAS) is recommended
as a key lifesaving intervention for children aged
What is already known on this topic?
▸ Vitamin A supplementation among children 6
to 59 months of age has been shown to reduce
under-ﬁve child mortality in populations at risk
of vitamin A deﬁciency.
▸ There is mixed evidence of the impact of
vitamin A supplementation in the newborn
period on mortality among children by 6
months of age, with studies in South Asia
(India, Philippines and Bangladesh) showing a
reduction in mortality but little evidence of a
similar effect among studies in Africa.
▸ A major issue in relation to neonatal vitamin A
dosing is the feasibility of administering such
doses as part of public sector programmes.
What this study adds?
▸ Our study was designed as a feasibility study
with possible inclusion within the Lady Health
Worker (LHW) programme of activities and
early post-natal visits in two rural districts of
Pakistan with populations at risk of vitamin A
deﬁciency.
▸ The LHWs were able to administer the vitamin
A dose to a large proportion (79%) of newborn
infants at home within 72 hours of birth with
no signiﬁcant adverse effects noted.
▸ There was no impact of neonatal Vitamin A
supplementation on mortality at 6 months of
age, although the proportion of days observed
with fever, diarrhoea or rapid breathing were
lower with neonatal vitamin A
supplementation.
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6–59 months in populations at risk of vitamin A deﬁciency.5
Given widespread maternal vitamin A deﬁciency in some
regions and the fact that a large proportion of child deaths
occur among young infants, it is plausible that alleviation of
vitamin A deﬁciency among young infants could be beneﬁcial.
Although some studies have reported a beneﬁcial impact on
infant mortality in south Asia and among populations with a
relatively high prevalence of maternal vitamin A deﬁciency,6 7
other recent studies have shown modest beneﬁts.8 These ﬁnd-
ings cannot be generalised to the global context as other rando-
mised controlled trials in similar settings have not shown any
beneﬁts.9–12
Pakistan has relatively high neonatal and under-5 child mor-
tality rates compared with other south Asian countries13 and a
persistent high burden of maternal and child vitamin A deﬁ-
ciency at the population level.14 In 1994 the Government of
Pakistan launched a national programme for family planning
and primary care, the so-called Lady Health Worker (LHW)
programme, with the objective of improving health and access
to essential primary health care in rural and selected peri-urban
communities. The LHWs are community-based health workers
with secondary education who are trained and employed by the
Ministry of Health to deliver these services.15 Each LHW is
responsible for a population of around 1000. The LHWs regis-
ter all pregnant women (pregnancies) in their catchment area
and, as part of their assignments, are supposed to undertake a
postnatal visit at the household level within 72 hours of birth,
although the overall coverage of this intervention is very low.16
LHWs are supervised by Lady Health Supervisors (LHSs)
employed at a Basic Health Unit (BHU). Each LHS is typically
responsible for 20–25 LHWs in her catchment area and super-
vises their overall work and monthly progress reports. The pro-
gramme is operational throughout the country and currently
employs over 100 000 LHWs. In June 2011, as part of a consti-
tutional amendment, the LHW programme was devolved to the
provinces. The national LHW programme is the mainstay of
many primary care preventive interventions in rural settings
and, while a number of newborn interventions have been
piloted through this programme,17 18 there are none that have
evaluated the feasibility and effectiveness of an early postnatal
visit and provision of a vitamin A supplement.
We undertook a community-based, placebo-controlled, cluster
randomised trial in rural Pakistan to evaluate the feasibility of
delivering early neonatal vitamin A (single dose of 50 000 inter-
national units (IU) or placebo) through LHWs and its potential
impact on health outcomes and mortality at 6 months of age.
METHODS
Context and population
The trial was conducted between January 2007 and October
2010 in two rural districts, Sukkur and Jhelum, in Pakistan,
representing a typical mix of peri-urban and rural multiethnic
populations of 1 108 000 and 1 048 000, respectively. The
intervention was developed and implemented in partnership
with the LHW programme and the study areas selected on the
basis of demographic patterns and population mix, number of
functional LHWs and approval by the LHW programme for
partnership and data sharing.
The LHWs and LHSs underwent 3 days of separate training
at the beginning of the project. The training focused on under-
standing the programme objectives for commodity delivery,
appropriate storage (light protection) for the capsules, transport
and administration of capsules, recognition and reporting of
adverse events, morbidities and hospitalisations. The LHWs
were trained to record morbidities reported by mothers cover-
ing the 2 weeks prior to the visit and to examine the newborn/
infant for relevant morbidities using the standard WHO/IMCI
algorithms for classiﬁcation of respiratory tract infections, sepsis
and diarrhoea. Refresher trainings (1 day) were provided during
the course of the study on a quarterly basis.
Study design, cluster deﬁnition, sample size estimation and
allocation
A baseline census of the study areas in both districts was under-
taken to enumerate households, collect socioeconomic and
demographic data and determine LHW density. Study clusters
were deﬁned as the catchment population of one LHW, usually
an average population of 1000 covering 100–150 households.
An external consultant generated the computerised allocation
sequence of clusters to each intervention group using Epi Info
3.5.3 with restricted randomisation based on population size,
expected births and LHW presence.
Given the reported rural infant mortality rates from the
Pakistan Demographic and Health Survey (2006)19 in the two
districts of about 80 per 1000 live births and a projected 25%
reduction in mortality at 6 months of age, we estimated that
400 clusters (200 in each group, averaging 30 births per cluster
annually) would be required to demonstrate this impact with
80% power and 5% signiﬁcance.20
Study procedures and data collection
Pregnant women were registered by LHWs as part of their
regular activities and standard operating procedures. Families
were encouraged to report a birth as soon as it occurred and
LHWs also liaised with the local traditional birth attendants to
identify births. The LHWs were encouraged to visit the birth
household (within 72 hours) following notiﬁcation of birth to
obtain written informed consent, collect information on the
mother and newborn, and to administer a single dose of oral
vitamin A (50 000 IU) or placebo to the infant. The LHW also
counselled the mother on basic preventive measures and encour-
aged her to breast feed the newborn immediately after capsule
administration to ensure consumption of the entire dose. All
live born infants within participating villages were potentially
eligible for inclusion in the study. Infants with obvious congeni-
tal malformations and birth weight <1500 g were excluded. No
vitamin A doses were administered in facilities, and for facility
births the LHW visited the household at least once within
72 hours of birth and, if the mother and infant pair had
returned from the hospital, she administered the neonatal dose.
The LHW returned empty vitamin A capsules to the LHS
who kept an inventory of the repository and provided supervi-
sion, capsule replenishment and monitored the LHW’s activities
as per routine. The LHW repeated the home visits on days 7
and 28 and thereafter at monthly intervals until 6 months of
age. On the ﬁrst follow-up visit at day 7 (unless passively
reported earlier by the family), the LHW collected information
on any adverse events reported by the mother after vitamin A
administration and thereafter information was collected on neo-
natal illnesses, care seeking, hospitalisations and any deaths at
the monthly visits. At each visit the infant’s vital status was eval-
uated, signs of illness (if any) recorded and action taken as per
LHW programme policies.
Blood samples from a randomly selected subset of 450 infants
were obtained at 6 months of age and analysed for serum
retinol concentration. The samples were collected at the house-
hold level by trained phlebotomists, separated and frozen in the
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ﬁeld and transported to the Nutrition Research Laboratory at
the Aga Khan University for analysis using standard methods.21
Masking, distribution of capsules and quality control
The vitamin A capsule contained 50 000 IU retinol palmitate in
soybean oil and the placebo contained 10 IU vitamin E in
soybean oil. The capsules were identical in appearance (Banner
Pharmacaps, Alberta, Canada) and supplied in bulk through the
courtesy of the Micronutrient Initiative (Ottawa, Canada). The
capsules were stored at the Aga Khan University (AKU) phar-
macy with close temperature regulation and light protection,
and supplied to the districts in similar containers with unique
codes representing clusters and speciﬁc LHWs. The content and
allocation of the capsules were masked from the investigators
and ﬁeld staff and the container codes were only known to the
external consultant responsible for cluster randomisation and
the chair of the Data Safety and Monitoring Board (DSMB).
The containers (vitamin A and placebo) were covered with alu-
minium foil and transported at room temperature to the ﬁeld at
monthly intervals based on requirement and consumption.
Research supervisors carried out random checks of vitamin A
stores to ensure compliance. Strict ﬁdelity of allocation of
vitamin A (or placebo) containers by LHWs was maintained by
the AKU pharmacy.
Data capture, trial safety monitoring and analysis
Twelve independent teams of data collectors (each with six
members including a supervisor) conducted a cross-sectional
household survey of the entire catchment population at baseline
and thereafter at 3-monthly intervals. The data collectors were
provided with 3 days of training on data collection instruments
and communication skills. These teams collected information on
live births, deaths, migrations and also obtained information on
causes of deaths through verbal autopsies. They obtained infor-
mation on receipt of vitamin A by newborn infants from
mothers/family elders. Additionally, a separate data collection
team visited the household at 2-weekly intervals to gather data
on morbidity and collect details of diarrhoeal episodes, respira-
tory problems and febrile episodes that the neonate/infant
encountered during the preceding 2 weeks.
The primary outcome was all-cause mortality by 6 months of
age Secondary outcomes were common morbidities (febrile
illness, diarrhoea or pneumonia). Infant deaths were identiﬁed
at home visits by LHWs and also veriﬁed by the independent
data collection team of all recruited children. In case of discrep-
ancy between LHW record and independent study data collec-
tors, the study supervisor veriﬁed deaths by household visits.
Cause of death was determined from an independent review of
verbal autopsies by two paediatricians. Disagreements were
referred to a third assessor experienced in verbal autopsies.
All data ﬁles were double entered in MS FoxPro and analysed
using STATA V.12, in addition to mortality outcomes at
6 months of age and morbidity data. The proportion of
monthly visits at which a child was reported to have had mor-
bidity was compared between the two arms using a Generalised
Estimating Equation, accounting for clusters, controlling for the
month of the visit (as a proxy for age).
The trial was overseen by a DSMB consisting of four
members with expertise in cluster randomised trials, newborn
and child health and medical statistics. The DSMB had access to
allocation codes and undertook blinded safety analyses to check
for any excess in mortality or severe morbidity outcomes. The
DSMB met three times during the course of the study to assess
progress, adverse events and key outcomes. The Chair of the
Figure 1 Flow diagram for the neonatal vitamin A study (Pakistan). *Two twins (1LB, 1SB), 31 twins (LB) and two triplets (LB). #24 twins (LB),
one twin (SB) and one triplet (LB). LB, live birth; SB, stillbirth.
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DSMB gave permission to unmask the study after completion of
the trial, data locking and analysis of primary outcomes. While
data on primary outcomes were available by November 2011,
given the LHW programme devolution to the provinces in
mid-2011, permission to share the results from the LHW pro-
grammes in Sindh and Punjab took considerably longer and was
ﬁnally received in April 2013.
RESULTS
The cross-sectional surveys identiﬁed 15 433 pregnant women
in the catchment area during the course of the study, of which
the LHWs registered a total of 13 225 pregnant women (86%).
Assessment of gestational age was based on the maternal recall
of her last menstrual period. Birth outcomes were recorded for
12 218 women (92%) while 1007 (8%) were lost to follow-up
and a further 374 (3.1%) pregnancies ended in stillbirths. The
remaining pregnancies resulted in 11 918 live born babies. Of
these, 171 live born babies (1.4%) died before the LHW con-
ducted the ﬁrst postnatal visit, with the majority of the neonatal
deaths (66.3% in the placebo group and 52.9% in neonatal VAS
group) occurring within the ﬁrst 24 hours of life. A further 609
(5.1%) neonates were excluded for other reasons (ﬁgure 1).
Altogether, 11 028 (92.5%) of all live born newborns were ran-
domised to receive either placebo or neonatal VAS capsules, of
which 10 286 (86.3%) infants were followed up until death or
6 months of age.
The baseline characteristics of the two study arms were com-
parable (table 1). Study participants in both the groups were
also comparable with respect to timing of interventions, gender
and BCG vaccination status. Overall, the majority of the deliver-
ies (55.2%) occurred at home, mostly attended by traditional
birth attendants. Among the newborns that had their weights
assessed at birth, mean recorded birth weights were 2.82 kg in
the placebo arm and 2.81 kg in the neonatal VAS arm; 8.3% of
infants were low birth weight (<2.5 kg) in the placebo arm
compared with 9.3% in the neonatal VAS arm (table 2).
Newborn infants in the community receive their ﬁrst dose of
polio and BCG at the BHUs by government employed vaccina-
tors and the BCG vaccination status for the two groups was
comparable.
The LHWs successfully delivered the capsules to the majority
(80%) of newborns (neonatal VAS/placebo) within 72 hours of
birth; 60% received them within 24 hours. A total of 26
adverse events were documented in the two groups, 10 in the
neonatal VAS group and 16 in the placebo group (p=0.19). Of
the 10 adverse events in the neonatal VAS group, seven were
diarrhoeal episodes. Only one case of bulging fontanel was
reported in each group (table 3).
We did not measure maternal or neonatal serum retinol con-
centrations at birth or recruitment. However, among the subset
of 449 infants sampled at 6 months of age, there was no evi-
dence of a difference in mean serum retinol concentrations
Table 1 Sociodemographic characteristics of the infants’ families pre-randomisation (baseline survey), n (%)
Characteristic Placebo (n=25 474) VAS (n=28 431)
Married women aged 15–49 years 23 877 26 076
Median (IQR) age, years 30 (25–40) 31 (26–40)
Maternal literacy 6623 (28%) 7544 (29%)
Household density 6.2 6.1
Monthly household income
≤6000 PKR 16 437/25 033 (67%) 18 814/28 260 (68%)
>6000 PKR 8227/25 033 (33%) 9028/28 260 (32%)
Median (IQR) 5000 (3000–8000) 5000 (3000–7000)
Nature of construction of household
Pucca (concrete) 14 289/25 431 (56%) 12 015/28 390 (42%)
Semi-pucca 5063/25 431 (20%) 11 251/28 390 (40%)
Katcha 5623/25 431 (22%) 4774/28 390 (17%)
Others 456/25 431 (2%) 350/28 390 (1%)
Living rooms in the house
1 8800/25 191 (35%) 8699/28 272 (31%)
≥2 16 365/25 191 (65%) 19 561/28 272 (69%)
Main cooking fuel
Electricity 3279/25 474 (13%) 3742/28 431 (13%)
Natural gas 4829/25 474 (19%) 3590/28 431 (13%)
Firewood 17 094/25 474 (67%) 20 764/28 431 (73%)
Others 216/25 474 (1%) 289/28 431 (1%)
Household with electricity 24 470/25 425 (96%) 27 816/28 399 (98%)
Main drinking water source
Well/hand pump 4552/25 429 (18%) 4826/28 387 (17%)
Communal tap/motor pump 14 978/25 429 (59%) 17 032/28 387 (60%)
Others 5900/25 429 (23%) 6529/28 387 (23%)
Type of latrine
Open fields 9133/25 427 (36%) 9918/28 385 (35%)
Pit latrine 3983/25 427 (16%) 4449/28 385 (16%)
WC connected to public sewerage/open drains 12 253/25 427 (48%) 13 970/28 385 (49%)
Data are n, n (%) or median (IQR).
N.B. The denominator can vary due to not reported responses.
VAS, vitamin A supplementation.
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Table 2 Baseline characteristics of mothers and delivery and newborn care practices (post-randomisation)
Characteristic Placebo VAS
Baseline characteristics of mothers (n=5962) (n=6256)
ANC visits during current pregnancy
Never 474/5693 (8%) 551/5947 (9%)
1–3 2658/5693 (47%) 2608/5947 (44%)
>3 2561/5693 (45%) 2788/5947 (47%)
Iron or multivitamin supplementation during current pregnancy
Yes 4342/5962 (73%) 4579/6256 (73%)
Addiction during pregnancy period
Tobacco 64 (1%) 52 (1%)
Non-smoking tobacco* 182 (3%) 143 (2%)
Reproductive history
Gravida, mean (SD) 2.51 (2.57) 2.49 (2.78)
Delivery and newborn care practices (n=5380) (n=5648)
Place of delivery
At home 2892/5341 (54%) 3169/5632 (56%)
Government health facility 715/5341 (13%) 838/5632 (15%)
Private hospital 930/5341 (17%) 908/5632 (16%)
Private clinic 804/5341 (15%) 717/5632 (13%)
Delivery attended
Skilled provider† 2779/5346 (52%) 2800/5628 (50%)
Unskilled 339/5346 (48%) 2828/5628 (50%)
Use of clean delivery kits 3508/5291 (66%) 3604/5420 (67%)
Gender of child
Male 2772/5378 (52%) 2965/5645 (53%)
Female 2606/5378 (49%) 2680/5645 (48%)
Birth weight (kg)
<2.5 306/3693 (8.3%) 331/3549 (9.3%)
≥2.5 3387/3693 (92%) 3218/3549 (91%)
Birth weight mean (SD), kg 2.82 (0.72) 2.81 (0.74)
BCG given to newborn after birth
Yes 1614/5370 (30%) 1629/5630 (29%)
Data are n, n (%) or mean (SD).
N.B. Denominator can vary due to not reported responses.
*Pan, niswar and gutka.
†Doctor, nurse and Lady Health Visitor.
VAS, vitamin A supplementation.
Table 3 Adverse events following vitamin A supplementation (VAS), n (%)
Placebo VAS p Value
Adverse event reported within 1 week of supplementation 16/5380 (0.3%) 10/5648 (0.2%) 0.2
(95% CI 0.2 to 0.5) (95% CI 0.1 to 0.3)
Distribution of adverse events
Loose motion 8/16 (50%) 7/10 (75%)
(95% CI 23 to 77) (95% CI 39 to 100)
Vomiting 2/16 (12.5%) 1/10 (10.0%)
(95% CI 0 to 30) (95% CI 0 to 31)
Bulging fontanel 1/16 (6%) 1/10 (10%)
(95% CI 0 to 19) (95% CI 0 to 31)
Unconsciousness 1/16 (6%) 0/10 (0%)
(95% CI 0 to 19) (95% CI – –)
Seizures 1/16 (6%) 1/10 (10%)
(95% CI 0 to 19) (95% CI 0 to 31)
Fever 3/16 (19%) 0/10 (0%)
(95% CI 0 to 40) (95% CI – –)
Hospitalisation during first 6 months of life 185/5380 (3.4%) 185/5648 (3.3%) 0.6
(95% CI 2.9 to 3.9) (95% CI 2.8 to 3.7)
Data are n or n (%).
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between the two groups (table 4). However, the proportion
with severe retinol deﬁciency was signiﬁcantly lower among the
VAS group.
There were no differences in reported morbidities between
the two arms of the study. The morbidity rates of diarrheal epi-
sodes, fever and rapid breathing and severe pneumonia were
similar in both groups (table 5). Neonatal deaths (0–28 days)
per protocol were comparable in both the placebo and
intervention arms (48 vs 57, p=0.59). Similarly, no difference
was documented in mortality at 0–6 months (115 vs 128,
p=0.64). The intention to treat analysis also revealed similar
results (table 6).
DISCUSSION
Our ﬁndings show that it was feasible for LHWs in Pakistan to
deliver vitamin A supplements to newborn infants within
Table 5 Reported morbidities by treatment arm
Placebo VAS OR* (VAS vs placebo) (95% CI)
Proportion of monthly visits at which child was reported to have been ill in preceding 30 days
Number of monthly visits completed 26 571 27 465
Fever 8130/26 571 (31%) 7928/27 465 (29%) 0.94 (0.76 to 1.16)) p=0.5
Diarrhoea 2609/26 571 (10%) 2272/27 465 (8%) 0.78 (0.57 to 1.08) p=0.1
Rapid breathing 740/26 571 (2.8%) 617/27 465 (2.3%) 0.92 (0.55 to 1.53) p=0.7
Severe pneumonia 245/26 571 (0.9%) 121/27 465 (0.4%) 0.42 (0.16 to 1.11) p=0.1
Data are n, n (%) or mean proportion of days with illness.
*OR estimated using Generalised Estimating Equation to account for cluster randomisation and adjusted for month of visit.
VAS, vitamin A supplementation.
Table 4 Serum retinol level at 6 months of age
Placebo (n=219) VAS (n=230) p Value
Retinol (mg/dL)
Severe deficiency (<10 mg/dL) 19/219 (9%) 79/230 (4%) 0.04
(95% CI 5 to 12) (95% CI 1 to 6)
Deficiency (<20 mg/dL) 82/219 (37%) 79/230 (34%) 0.5
(95% CI 31 to 44) (95% CI 28 to 41)
Mean (SE) 25.7 (0.87) 26.9 (0.99) 0.4
(95% CI 24 to 28) (95% CI 25 to 29)
Median (IQR) 23.7 (16.4 to 33.3) 23.7 (16.8 to 32.8)
Data are n, n (%) or mean (SE) or median (IQR).
VAS, vitamin A supplementation.
Table 6 Effect of vitamin A post-supplementation on primary outcome: overall and stratified by sex
Number of newborns supplemented Risk per 1000 live births
p Value
Effect size
(95% CI)
Placebo VAS
Placebo VAS
OR
(95% CI)Events No of newborns Events No of newborns
Mortality (post-supplementation)
A. Neonatal mortality (0–28 days)
Overall 48 5380 57 5648 9 (95% CI 7 to 12) 10 (95% CI 8 to 13) 1.13 (0.76 to 1.66) 0.6 0.06 (−0.14 to 0.28)
Male 21 2774 26 2966 7.6 (95% CI 5 to 12) 8.8 (95% CI 6 to 13) 1.15 (0.65 to 2.06) 0.6 0.08 (−0.23 to 0.39)
Female 27 2606 31 2682 10.4 (95% CI 7 to 15) 11.6 (95% CI 8 to 16) 1.11 (0.66 to 1.87) 0.7 0.06 (−0.22 to 0.34)
B. Mortality (0–6 months)
Overall 115 5380 128 5648 21 (95% CI 18 to 26) 23 (95% CI 19 to 27) 1.06 (0.82 to 1.37) 0.6 0.03 (−0.10 to 0.17)
Male 49 2774 58 2966 17.7 (95% CI 13 to 23) 19.6 (95% CI 15 to 25) 1.10 (0.75 to 1.62) 0.6 0.05 (−0.15 to 0.26)
Female 66 2606 70 2682 25.3 (95% CI 20 to 32) 26.1 (95% CI 21 to 33) 1.03 (0.73 to 1.44) 0.9 0.01 (−0.17 to 0.20)
Mortality (pre- and post-supplementation)
C. Neonatal mortality (0–28 days)
Overall 134 5706 142 5970 23 (95% CI 20 to 28) 24 (95% CI 20 to 28) 1.01 (0.80 to 1.27) 0.9 0.007 (−0.12. 0.13)
Male 73 2959 75 3145 25 (95% CI 20 to 31) 24 (95% CI 19 to 30) 0.96 (0.69 to 1.33) 0.8 −0.01 (−0.19 to 0.16)
Female 61 2747 67 2825 22.2 (95% CI 17 to 28) 23.7 (95% CI 19 to 30) 1.06 (0.75 to 1.52) 0.7 0.03 (−0.15 to 0.23)
D. Mortality (0–6 months)
Overall 201 5706 213 5970 35 (95% CI 31 to 40) 36 (95% CI 31 to 41) 1.03 (0.83 to 1.23) 0.9 0.007 (−0.10 to 0.11)
Male 101 2959 107 3145 34 (95% CI 28 to 41) 34 (95% CI 28 to 41) 0.99 (0.75 to 1.31) 1.0 −0.002 (−0.15 to 0.15)
Female 100 2747 106 2825 36 (95% CI 30 to 44) 38 (95% CI 31 to 45) 1.03 (0.78 to 1.36) 0.8 0.01 (−0.13 to 0.17)
VAS, vitamin A supplementation.
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72 hours of birth. Given the importance attached to postnatal
visits in terms of impact on newborn survival,22 this is an
important step in developing integrated packages for preventive
care after birth. Thus the addition of neonatal vitamin A dosing
to the repertoire of interventions that can be implemented in
the immediate postnatal period and the ﬁrst few days of life (eg,
cord chlorhexidine application,19 breastfeeding promotion and
oral polio, BCG and hepatitis B vaccines) is both feasible and
potentially cost-effective. The LHWs and families did not
report any signiﬁcant adverse effects with the 50 000 IU dose.
Only one case was reported to have a bulging fontanel, which
self-resolved within 72 hours, while another case of vomiting
and suspected seizures was found to be well at examination and
resolved within 24 hours. These data suggest that, overall, neo-
natal VAS is a safe intervention that can be administered by
community health workers in community settings.
The key question is whether the intervention is effective with
health and survival beneﬁts. We did not ﬁnd any impact on mor-
tality at 6 months of age and the observed effects on morbidity
were also marginal and non-signiﬁcant. Several limitations must
be recognised in our study. Our trial was designed to assess the
feasibility and effectiveness in a large rural district but had a
smaller sample size than other similar studies.7 We did not
measure vitamin A status in mothers or newborns at baseline
and hence it is difﬁcult to ascertain the extent to which bio-
chemical vitamin A deﬁciency was widespread in the target
population. However, a recent national nutrition survey includ-
ing these very districts has highlighted vitamin A deﬁciency on
serum retinol estimation of 42.5% and 54% among women of
reproductive age and children <5 years, respectively, from this
district.14
A similar burden has been documented in Africa with vitamin
A deﬁciency as high as 43% with a higher prevalence in the
rural population. Others have demonstrated somewhat lower
levels.24 25
Our ﬁndings of a lack of signiﬁcant beneﬁt of neonatal VAS
on survival at 6 months of age is at variance with other studies
in south Asia.6–8 However, other studies in Africa have failed to
show any beneﬁts of neonatal VAS on survival.10 23 26 Although
some reviews have failed to show any mortality beneﬁt of neo-
natal VAS,27 our previous assessment of the evidence suggested
geographical variation in the response to neonatal VAS which
could relate to prevalent maternal vitamin A or multiple micro-
nutrient deﬁciencies.28 29 Although some gender-related differ-
ences in outcomes and survival have been reported,30 we did
not ﬁnd any differences in outcomes among female infants.
Previous studies of neonatal VAS have also reported mixed
results on morbidity patterns. In Indonesia, neonatal VAS was
associated with a reduced number of clinic visits.29 31 Our data
on morbidity patterns also did not show any reduction in mor-
bidity rates or hospitalisations with neonatal VAS.
Breast feeding provides protection against vitamin A deﬁ-
ciency even in populations where deﬁciency may be endemic.
Our study population had almost universal breast feeding (98%)
in both the placebo and VAS arms. The lack of apparent beneﬁt
on mortality may also be because of protection from vitamin A
deﬁciency conferred by exclusive breast feeding early in life.
The blood samples at 6 months of age did show an impact on
the proportion with severe vitamin A deﬁciency among the sup-
plemented infants.
CONCLUSION
We conclude that the delivery and distribution of vitamin A is
feasible through the public sector LHWs. However,
recommendations with regard its inclusion in the repertoire of
interventions must await further evidence of beneﬁts and risks.
Our study did not show any beneﬁt on infant survival. Two of
three large trials evaluating the impact of vitamin A on infant
mortality have recently been published, demonstrating no bene-
ﬁts,10 26 although the study in India was associated with a 10%
reduction in mortality at 6 months of age,8 once again lending
support to the contention that the intervention may be relevant
in populations with varying rates of maternal nutritional risks
and vitamin A deﬁciency. Further recommendations on neonatal
VAS must therefore await additional contextual analysis and tar-
geting to populations at greatest risk, as well as comparison with
alternative strategies.29 32
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